Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development

Within the European Immunogenicity Platform (EIP) (http://www.e-i-p.eu), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-P...

Descripción completa

Detalles Bibliográficos
Autores principales: den Engelsman, John, Garidel, Patrick, Smulders, Ronald, Koll, Hans, Smith, Bryan, Bassarab, Stefan, Seidl, Andreas, Hainzl, Otmar, Jiskoot, Wim
Formato: Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063870/
https://www.ncbi.nlm.nih.gov/pubmed/20972611
http://dx.doi.org/10.1007/s11095-010-0297-1
Descripción
Sumario:Within the European Immunogenicity Platform (EIP) (http://www.e-i-p.eu), the Protein Characterization Subcommittee (EIP-PCS) has been established to discuss and exchange experience of protein characterization in relation to unwanted immunogenicity. In this commentary, we, as representatives of EIP-PCS, review the current state of methods for analysis of protein aggregates. Moreover, we elaborate on why these methods should be used during product development and make recommendations to the biotech community with regard to strategies for their application during the development of protein therapeutics.

Ejemplares similares